John P. Schmid bought $100k of DSGN
director at Design Therapeutics, Inc.. 26,965 shares at an average of $3.70, traded Mar 22, 2024, filed Mar 25, 2024.
Score components
- +15RoleDirector
- +10Trade size$100k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context53% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.4%, 3m -10.2%, 6m +43.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-009063, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 22, 2024 | POpen-market purchase Common Stockindirect: By Schmid Family Trust U/A dated 8-15-17 | +9,156 | $3.62 | $33k | 9,156 | Mar 25, 2024 |
| Mar 25, 2024 | POpen-market purchase Common Stockindirect: By Schmid Family Trust U/A dated 8-15-17 | +17,809 | $3.74 | $67k | 26,965 | Mar 25, 2024 |
Related signals
Other insiders at Design Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | DSGNsell Design Therapeutics, Inc. | Arsani William director | $3.0M 562,627 shares | -19% | |
| 20Weak | DSGNsell Design Therapeutics, Inc. | Deepa Prasad director | $24k 3,806 shares | -16% | |
| 60Notable | DSGNsell Design Therapeutics, Inc. | Arsani William director | $3.5M 814,874 shares | -100% | |
| 39Weak | Design Therapeutics, Inc. | Heather A. Berger director | $4,866 1,300 shares | - | |
| 69Notable | Design Therapeutics, Inc. | Joao Siffert MD President and CEO | $63k 7,450 shares | +6% | |
| 58Moderate | Design Therapeutics, Inc. | SR One Capital Fund I Aggregator LP owner | $7.6M 900,000 shares | +16% | |
| 66Notable | Design Therapeutics, Inc. | Simeon George director, owner | $7.6M 900,000 shares | +16% | |
| 61Notable | Design Therapeutics, Inc. | Rodney W Lappe director | $119k 15,000 shares | +15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.